Mitochondrial DNA (mtDNA) depletion syndrome (MDS) is characterized by a reduction in mtDNA copy number and consequent mitochondrial dysfunction in affected tissues. A subgroup of MDS is caused by mutations in genes that disrupt deoxyribonucleotide metabolism, which ultimately leads to limited availability of one or several deoxyribonucleoside triphosphates (dNTPs), and subsequent mtDNA depletion. Here, using in vitro experimental approaches (primary cell culture of deoxyguanosine kinase-deficient cells and thymidine-induced mtDNA depletion in culture as a model of mitochondrial neurogastrointestinal encephalomyopathy, MNGIE), we show that supplements of those deoxyribonucleosides (dNs) involved in each biochemical defect (deoxyguanosine or deoxycytidine, dCtd) prevents mtDNA copy number reduction. Similar effects can be obtained by specific inhibition of dN catabolism using tetrahydrouridine (THU; inhibitor of cytidine deaminase) or immucillin H (inhibitor of purine nucleoside phosphorylase). In addition, using an MNGIE animal model, we provide evidence that mitochondrial dNTP content can be modulated in vivo by systemic administration of dCtd or THU. In spite of the severity associated with diseases due to defects in mtDNA replication, there are currently no effective therapeutic options available. Only in the case of MNGIE, allogeneic hematopoietic stem cell transplantation has proven efficient as a long-term therapeutic strategy. We propose increasing cellular availability of the deficient dNTP precursor by direct administration of the dN or inhibition of its catabolism, as a potential treatment for mtDNA depletion syndrome caused by defects in dNTP metabolism.
INTRODUCTION
Mitochondrial DNA (mtDNA) depletion syndrome (MDS) comprises several severe autosomal diseases characterized by a reduction in mtDNA copy number in affected tissues. Most of the MDS causative nuclear genes encode proteins that belong to the mtDNA replication machinery or are involved in deoxyribonucleoside triphosphate (dNTP) metabolism.
The mitochondrial dNTP pool size and composition in nonproliferating tissues depend on a balance between dNTPs produced by anabolic mitochondrial and cytosolic pathways and consumed by incorporation into mtDNA or catabolism (Fig. 1) . Some forms of MDS are caused by mutations in genes encoding anabolic enzymes: TK2 (encoding thymidine kinase 2, TK2), DGUOK (encoding deoxyguanosine kinase, dGK) and RRM2B (encoding p53R2, the p53-inducible small subunit of ribonucleotide reductase, RNR) (1 -3) . In contrast, mutations in TYMP (encoding thymidine phosphorylase, TP) cause mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) (4) .
TP catalyzes the first reaction in catabolism of the pyrimidine deoxyribonucleosides (dNs), thymidine (dThd) and deoxyuridine (dUrd), and its dysfunction leads to increased deoxythymidine triphosphate (dTTP) (5, 6 ) and a secondary decrease in mitochondrial deoxycytidine triphosphate (dCTP), which results in mtDNA depletion (7) . Hence, a limited availability of one or more dNTPs is the common mechanism accounting for mtDNA depletion due to defective mitochondrial dNTP homeostasis.
The therapy options for MDS are mainly symptomatic or invasive (8) . Previous experimental studies have shown that bypassing the defective step in deoxyribonucleotide biosynthesis can ameliorate mtDNA depletion. Addition of purine dN monophosphates (dNMPs) to the cell culture medium has been found to rescue mtDNA depletion in dGK-deficient cells (9 -12) . Other studies suggest that mtDNA depletion can be prevented by supplying an excess of dNs, indicating that the cytosolic salvage pathway (and/or residual mitochondrial salvage activity) may be enhanced by increasing the substrate availability (7, 13, 14) . Here, we provide evidence that the use of dNs and/or specific inhibitors of their catabolism may be an effective pharmacological approach for treating MDS due to defects in dNTP homeostasis.
RESULTS
In a previous study, we found that dThd-induced mtDNA depletion can be prevented or reverted by deoxycytidine (dCtd) in cell culture and proposed that treatment with this nucleoside could prevent mtDNA depletion in MNGIE (7) . However, rapid dCtd deamination by the ubiquitous enzyme cytidine deaminase (CDA) would limit dCtd availability in vivo. For this reason, we tested the effect of the CDA inhibitor tetrahydrouridine (THU) on the mtDNA copy number in the same cell model. MtDNA depletion was induced in quiescent human skin fibroblasts by exposing them to dThd. Cells were treated with 5 mM THU, alone or in combination with a range of dCtd concentrations (0, 1, 5, 20 mM). As was expected, THU partially prevented catabolism of both endogenous and added dCtd, increasing dCtd levels in the medium and reducing dUrd accumulation ( Table 1) . As for the effect on mtDNA under dThd treatment, cotreatment with dCtd prevented mtDNA depletion ( Fig. 2A) , as has been reported (7). An additional experiment using 5 mM [6-3 H]-dCtd and THU allowed us to confirm that the added dN is incorporated into DNA (data not shown). In addition, THU alone partially counteracted the effect of dThd on mtDNA copy number, indicating that Figure 1 . Representation of the main dNTP metabolic pathways. Catabolic enzymes are marked in boxes and inhibitors used in this study are written in gray italics. ADA, adenosine deaminase; CDA, cytidine deaminase; dAdo, deoxyadenosine; dCK, deoxycytidine kinase; dCtd, deoxycytidine; dCTD, deoxycytidylate deaminase; dGK, deoxyguanosine kinase; dGuo, deoxyguanosine; dIno, deoxyinosine; dThd, thymidine; dUrd, deoxyuridine; EHNA, erythro-9-(2-hydroxy-3-nonyl) adenine; ENT1, equilibrative nucleoside transporter 1; IH, Immucillin H; PNP, purine nucleoside phosphorylase; RNR, ribonucleotide reductase; THU, tetrahydrouridine; TK1, thymidine kinase 1; TK2, thymidine kinase 2; TP, thymidine phosphorylase; TS, thymidylate synthase.
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the moderate THU-induced increase of endogenous dCtd noticeably influenced mtDNA replication. However, THU addition did not produce any appreciable synergistic-positive effect over only dCtd addition at the concentrations tested ( Fig. 2A ).
These data indicate that, in our experimental conditions, addition of 1 mM dCtd probably exceeds the needs to achieve mitochondrial dCTP concentrations above those that limit the mtDNA replication rate. We used a double Tymp/Upp1 knockout murine model of MNGIE (5) to test the in vivo effect of dCtd or THU administration on dNTP imbalances. A single dose of 100 mg/kg THU resulted in a 3-fold increase of plasma dCtd 3 h after injection, concomitant with a 50% reduction of circulating dUrd (Fig. 2B) , which indicates that a major source of dUrd in double KO mice is dCtd deamination. A similar increase of plasma dCtd concentration was observed after a single injection of 400 mg/kg dCtd; however, most of the dCtd had been rapidly deaminated, as plasma dUrd concentrations were between 9-and 80-fold higher than those of dCtd. When dCtd (400 mg/kg) and THU (100 mg/kg) were co-administered, dCtd deamination was largely prevented. Importantly, mitochondrial dCTP levels increased in response to the elevated systemic dCtd concentrations (Fig. 2C ). Significant dCTP increases were observed in liver and brain mitochondria, which correlated with dCtd levels (r ¼ 0.926, P , 0.001 for liver; r ¼ 0.853, P ¼ 0.001 for brain). Therefore, dCtd or THU, either individually or coadministered, can be used to increase mitochondrial dCTP. It is noteworthy that mitochondrial dATP, dTTP and dGTP were unaffected or only slightly modified by the treatments. A slight tendency to increase was only observed for dTTP and dGTP (Supplementary Material, Fig. S1 ).
After dCtd or THU administration, CDA or dCMP deaminase activities may lead to undesired dUTP expansion, but we could not detect dUTP in liver or brain mitochondria in any of the treated animals (,5 pmol/mg prot), probably due to the action of highly efficient dUTPases.
It has been repeatedly reported that treatment with dAMP + dGMP prevents mtDNA depletion in dGK-deficient cultured cells (9) (10) (11) (12) . Our results demonstrate that complete prevention of mtDNA depletion is achieved by addition of 50 mM dGuo alone to the culture, and that deoxyadenosine (dAdo) addition does not have any detectable effect (Fig. 3A) . Addition of 50 mM dGuo was also sufficient to restore mtDNA copy number in already depleted dGK-deficient fibroblasts (Supplementary Material, Fig. S2 ). The positive effects of 50 mM dGuo or 200 mM dGMP on dGK-deficient cells were comparable, but addition of 200 mM dAMP did not improve mtDNA copy number, similar to the lack of dAdo effect on mtDNA levels (Fig. 3B) .
Analysis of intracellular and extracellular levels of dAMP, dAdo, dGMP and dGuo 24 h after their addition to cell culture revealed that (Table 2 ): (i) dAMP and dGMP were undetectable in cell culture medium and cell homogenates; (ii) addition of dGMP or dGuo to the culture resulted in pronounced, dosedependent extracellular and intracellular dGuo increases, and the amounts did not depend on the chemical form of the added nucleoside, that is, unphosphorylated (dGuo) or phosphorylated (dGMP); and (iii) intracellular dAdo was undetectable and dramatically reduced in the medium 24 h after dAdo or dAMP addition. Additional experiments showed that high percentages of dAMP (25 -85%) and dGMP (15 -50%) are degraded over 24 h when added to conditioned medium without cells (Table 2 ). These results indicate that dNMPs are rapidly dephosphorylated in cell culture medium and strongly suggest that dephosphorylation mainly occurs extracellularly.
Given the positive effects that CDA inhibition had on mtDNA copy number in the MNGIE cell model, we tested whether inhibition of dGuo catabolism with the purine nucleoside phosphorylase (PNP) inhibitor immucillin H (IH) had a similar positive effect in dGK-deficient cells. Addition of a low concentration of dGuo (1 mM) to cell culture media had no detectable effects on mtDNA. However, cotreatment with 1 mM dGuo plus IH partially prevented mtDNA depletion in the cells (Fig. 4A ). Addition of dGuo at a higher concentration (50 mM) produced a more pronounced effect that was not improved by cotreatment with IH. Analysis of the culture medium confirmed that IH prevents dGuo catabolism ( Table 3) , and that addition of 1 mM dGuo is suboptimal in this model, but addition of 50 mM dGuo exceeds the level required to completely prevent mtDNA depletion in dGK-deficient cells. Similarly, in additional experiments in which cell medium was not replaced for 21 days, IH treatment induced a mild accumulation of endogenous dGuo (0.5 + 0.2 mM) that led to a 153 + 23% increase in mtDNA copy number relative to untreated cells. Overall, these results indicate that mtDNA copy number responds to dGuo concentration in a dose-dependent manner, and that IH may be helpful in preventing degradation of endogenous or added dGuo.
Our results (Fig. 3A ) also demonstrated that dAdo, alone or in combination with dGuo, does not have an effect on mtDNA copy number in dGK-deficient cells. Because dAdo is rapidly degraded by adenosine deaminase (ADA), we studied the effect of ADA inhibition using erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) ( Fig. 4B and Table 4 ). Addition of 50 mM dAdo in combination with EHNA substantially preserved dAdo in the culture medium (Table 4) . However, increased dAdo concentration in the medium not only failed to exert a positive effect, but rather slightly reduced mtDNA copy number (Fig. 4B) .
We analyzed DCK and DGUOK expression in the cultured cells used in our experiments. No differences in the relative DCK mRNA levels were detected between controls (1.0 + 0.1, mean + SD) and dGK-deficient cells (1.2 + 0.7), nor in DGUOK mRNA levels (controls 0.9 + 0.2 and dGK deficient 1.1 + 0.4). Treatment with 50 mM dGuo over 7 days did not affect the expression of these genes (treated controls, DCK mRNA 0.9 + 0.2 and DGUOK mRNA 0.9 + 0.3; treated dGK deficient, DCK mRNA 1.0 + 0.1 and DGUOK mRNA 1.1 + 0.1).
DISCUSSION
Previous data from our and other groups indicate that the ultimate cause leading to mtDNA depletion due to defective nucleotide metabolism is the limited availability of one or more of the dNTPs being used as substrates for DNA synthesis (7, 14) . The administration of the required dN may be sufficient to counteract dNTPs deficiency and thus mtDNA depletion. Once incorporated in the cell through dedicated transporters, increased dN concentration would enhance their phosphorylation by dN kinases in the cytosolic or mitochondrial salvage pathways to generate dNTPs. This study shows that addition of specific dNs and/or inhibition of their catabolism prevents mtDNA depletion in two different cell models: dThd-induced mtDNA depletion in fibroblasts from healthy controls (MNGIE cell model), and spontaneous mtDNA depletion in dGK-deficient fibroblasts. In MNGIE cells, dCTP deficiency is caused by the inhibition of We also observed that dGuo is as effective as dGMP for preventing mtDNA depletion in dGK-deficient cells. Our results strongly support the notion that dGMP, rather than exerting a positive effect on its own, ultimately acts as a source of dGuo, providing substrate for salvage kinases. Charged nucleotides cannot diffuse across biological membranes, and there is no experimental evidence of dNMP transporters in plasma membranes. In fact, nucleoside monophosphate analogs used as antiviral prodrugs require charge masking groups to allow their delivery across plasma membranes (15) . We show that dNMPs are rapidly dephosphorylated to dNs in cell culture, probably by factors excreted by the cells although membranebound activities, such as ecto-nucleotidases (16), may contribute to this dephosphorylation.
As previously discussed, a potential strategy for the treatment of MDS would be administration of specific dNs based on the patient's genetic defect. However, the bioavailability of these substances could be challenged by ubiquitous dN catabolic enzymes. Enzyme inhibitors such as THU and IH, originally used in chemotherapy, increase plasma concentrations of dCtd and dGuo, respectively (17, 18) . Hence, inhibition of catabolism stabilizes coadministered dNs, induces a sufficient increase in their endogenous concentrations, or both.
The bioavailability of the administered substance and its impact on the mitochondrial dNTP pool in targeted tissues cannot be investigated in cell culture. For this reason, we studied an MNGIE murine model and found that mitochondrial dNTPs can be manipulated in vivo by administration of the corresponding dN and/or inhibition of its catabolism. Based on our results, we propose that a sustained increase in systemic dCtd using this strategy could restore normal dCTP levels in mitochondria, thus preventing mtDNA depletion in MNGIE. Importantly, the increased dCtd concentration did not produce dTTP depletion, a finding consistent with the fact that dCtd is a poor competitor of dThd phosphorylation by TK2 (19) . THU would have the additional positive effect of reducing the dUrd accumulation observed in these patients. Therefore, we propose a treatment based on THU, alone or in combination with low doses of dCtd, to prevent further progression of mtDNA depletion in MNGIE patients. A possible drawback of either MNGIE or dGK-deficient therapies based on dNs supply, is that they both may rely on dCK activity, an enzyme which is poorly expressed in some typically affected tissues (20) . However, we have observed correction of mtDNA depletion in fibroblasts, where dCK expression level did not appear to be higher than that of dGK. More importantly, in our in vivo model, dCtd administration induces a clear increase in mitochondrial dCTP content in brain and liver, supporting the notion that, even if lowly expressed, dCK activity may be sufficiently enhanced by increased substrate availability.
Careful studies will be needed to ensure an absence of undesirable secondary effects of these therapies, especially regarding inhibitors of dN catabolism. Although CDA deficiency has not been associated with human disease, PNP dysfunction causes immunodeficiency (21) . Therefore, the consequences of IH dosage would need to be carefully studied and eventually modulated, as this therapy would have to be administered chronically. It is possible that total inhibition of the catabolic enzyme may not be required, and the combined treatment would likely lower inhibitor requirements.
Taken together, our results indicate that the appropriate dNs and/or inhibitors of their catabolism are good candidates for pharmacological treatment of MDSs due to defective nucleotide metabolism. We provide here direct biochemical and molecular evidence of the positive effects of this strategy in two of these disorders (loss-of-function mutations in TYMP and DGUOK), but the concept could be extended to other diseases affecting similar pathways, such as those caused by mutations in the TK2 and RRM2B genes.
MATERIALS AND METHODS

Ethics statement
This study was performed in accordance with the rules established by the Generalitat de Catalunya for the Care and Use of Laboratory Animals. The protocol was approved by the Committee on the Ethics of Animal Experiments of the Vall d'Hebron Research Institute (Permit Number: 14/13).
Cell culture
Primary human skin fibroblast cultures from three patients with DGUOK mutations and four healthy controls were used. Patient 1 had a homozygous c.749T.C mutation; p.L250S (709T.C in the original publication (22)), Patient 2 carried the mutation c.677A.G; p.H226R in homozygosity (cells kindly provided by Dr Antònia Ribes, mutation previously described for a Fibroblasts were seeded in 3.5-cm diameter plates (100 000 cells per plate) and expanded in DMEM with 4.5 g/l glucose, supplemented with 2 mM L-glutamine, 100 U/ml penicillin and streptomycin and 10% dialyzed FBS (Invitrogen) in a humidified incubator at 378C and 5% CO 2 . After tight confluence was reached, FBS was reduced to 0.1% to induce quiescence. Four days later (Day 0), the specific nucleoside or drug treatment was added to the cell medium. All treatments were performed in duplicate. The following compounds were added to the cell media at the concentrations indicated in the Results section: THU (BioVision), IH (gift from Prof. Vern Schramm, Albert Einstein College of Medicine, New York, USA), dAdo, dGuo, dAMP, dGMP, dCtd and EHNA (Sigma-Aldrich). During the treatment period, cell media (and respective additives) were replaced every 3 -4 days unless otherwise stated. At the times required according to the experimental designs, media were collected and stored at 2208C until further use. For DNA analysis, cells were harvested by trypsinization, washed with phosphatebuffered saline, pelleted and stored at 2208C until DNA isolation. For determination of dNs and dNMPs in medium and cell homogenates, see the specific section below.
dCtd and THU administration in vivo
Male Tymp/Upp1 double-knockout (5) and wild-type mice, aged 10-15 weeks, were administered a single dose of dCtd (400 mg/ kg in PBS), THU (100 mg/kg in PBS) or combined dCtd plus THU treatment (400 and 100 mg/kg in PBS, respectively) through the tail vein. Three hours after injection, mice were killed by cervical dislocation and tissues were processed as follows: 200-400 ml of blood was rapidly collected by cardiac puncture in EDTA (Microvette capillary tubes, SARSTEDT), whole anticoagulated blood was 1:3 diluted in PBS, and the diluted plasma was separated by centrifugation and kept at 2208C until further use. Brain and liver were rapidly dissected and immersed in mitochondrial extraction buffer for subsequent immediate mitochondrial isolation.
Mitochondrial isolation and dNTP quantification
Mitochondrial fractions from mouse liver and brain were isolated by differential centrifugation in A and AT buffer, respectively (buffer A: 320 mM sucrose, 1 mM EDTA and 10 mM TrisHCl, pH 7.4; buffer AT: 75 mM sucrose, 225 mM sorbitol, 1 mM EGTA, 0.1% fatty acid-free BSA and 10 mM Tris -HCl, pH 7.4), as described (7). The isolation procedure and further steps were performed at 48C. A 0.5-mg amount of protein from the mitochondrial suspensions was treated with trichloroacetic acid 0.5 M (final concentration), and centrifuged at 20 000g for 5 min at 48C. Supernatants were neutralized by vortexing with 1.5 volumes of 0.5 M trioctylamine in Freon (1,1,2-trichlorotrifluoroethane) and centrifuged for 10 min at 10 000g at 48C. Half of the upper aqueous phase was then collected to avoid contamination from the organic phase. The neutralized aqueous extracts were dried under speed-vacuum and dry residues were redissolved in 125 ml of 40 mM Tris -HCl (pH 7.4) and stored at 2808C until analysis. dNTP concentrations were determined using a polymerase-based method on an adequate amount of mitochondrial extract (ranging from the equivalent of 20-60 mg protein), as described (7) . For dUTP determination, one aliquot of the extract was treated with 0.25 units of dUTPase (ProsPec) at 488C for 30 min to eliminate any dUTP present in the sample. dTTP was then measured, and the result was compared with the results obtained for another aliquot without dUTPase treatment, which represented the total dTTP + dUTP content. The dUTP detection limit was 5 pmol/mg of mitochondrial protein.
Quantification of mtDNA copy number and mRNA levels by real-time PCR Total DNA was isolated from cell pellets (QuiAmpDNA Mini kit, Qiagen), dissolved in 10 mM Tris-HCl (pH 8.0) and quantified by spectrophotometry (NanoDrop Spectrophotometer, Thermo Scientific). Duplicates were assessed for each experimental condition. Real-time PCR was performed using an ABI PRISM w 7900HT sequence detector (Applied Biosystems). Detection of mtDNA and nuclear DNA was performed as a multiplex PCR reaction. TaqMan Universal PCR Master Mix with UNG (Applied Biosystems) and custom-designed sets of TaqMan probes and primers were used for relative mtDNA (12S rRNA gene) versus nuclear DNA (RNase P single copy gene) copy number quantification, as described (7) . A standard curve with cloned-12S and RNAse P amplicons was used for absolute quantification of mtDNA and nuclear DNA in the samples. RNA was isolated from quiescent fibroblasts with Trizol Reagent (Invitrogen) and resuspended in RNAase-free water. Two micrograms of RNA were treated with DNase I (DNase I Amplification grade, Invitrogen) and reverse Concentrations of dAdo and its metabolites, deoxyinosine (dIno), and hypoxanthine in cell culture media after treatment with 50 mM dAdo and/or 5 mM EHNA over 3 days. Results are the mean + SEM values from 3 dGK deficient and four independent control cell lines. Und, undetectable levels of analyte.
transcribed to cDNA by using the High-Capacity cDNA Archive kit (Applied Biosystems). Quantitative real-time PCR reactions were carried out in 384-well plates with the TaqMan Universal PCR Master Mix No Amperase UNG (Applied Biosystems). Predesigned-TaqMan Gene Expression Assays (Applied Biosystems) were used for the detection of DCK (Hs01040726_m1) and DGUOK (Hs00176514_m1) mRNAs. Each sample was analyzed in triplicates, and the average value was used to determine the level of mRNA. The amount of the specific mRNA in each sample was normalized to 18S rRNA (Hs99999901_s1) with the 2-DCT method for comparison. All samples included in an independent 384-well plate were referred to an untreated control sample to avoid inter-plate variation.
dN and dNMP determination dNMPs, dNs and some related metabolites were measured by liquid chromatography coupled to tandem mass spectrometry (LC -MS/MS), using an Acquity UPLC-MS/MS apparatus (Acquity UPLC-Xevo TM TQ Mass Spectrometer, Waters, Milford, MA, USA). Cell medium and diluted mouse plasma samples were prepared as previously described. For intracellular dN and dNMP determinations, 60 cm 2 cell monolayers were washed three times with ice-cold PBS in a cold room. Cells were then scraped from the dishes with 250 ml of ice-cold deionized Milli-Q water (Millipore). Collected cells were homogenized by 10 passes through a 23 G × 1 in. (0.6 × 25 mm) needle fitted to a syringe, homogenates were centrifuged at 13 000g at 48C for 5 min, and supernatants were stored at 2808C until further use. Protein concentration was measured by the Bradford method. Cell medium, diluted plasma and cell homogenates were deproteinized by ultrafiltration (3 kDa Amicon Ultra filters, Millipore) at 14 000g and 48C for 30 min before injection in the LC -MS/MS system. For all determinations, the stationary phase was an Acquity UPLC BEH C18 column (100 × 2.1 mm, 130 Å pore, 1.7 mm particle, Waters). For dN and metabolite determinations, 5 ml of deproteinized sample was injected into the LC -MS/MS system and resolved at 0.5 ml/min through a binary gradient elution using a saline buffer (20 mM ammonium acetate, pH 5.6) and acetonitrile as follows: time 0 -1.1 min, isocratic 100% saline buffer; 1.1 -5 min, gradient from 0 to 13.6% acetonitrile; 5 -5.1 min, gradient from 13.6 to 100% acetonitrile; 5.1-6.1 min, isocratic 100% acetonitrile; and 6.1 -7.2 min, isocratic 100% saline buffer. Detection of the eluate components was performed using multiple reaction monitoring, with positive electrospray mode with the following m/z transitions: 251.8 . 136.1 (dAdo), 227.9 . 112.1 (dCtd), 242.8 . 127.1 (dThd), 267.9 . 152.1 (dGuo), 136.8 . 110.1 (hypoxanthine), 136.8 . 110.1 (dIno) and 228.8 . 113.1 (dUrd). Identification of dIno and hypoxanthine with equal m/z transitions was based on different retention times. dNMPs were resolved and determined with the same column and an ion pairing-based elution using N,N-dimethylhexylamine (DMHA). Briefly, eluent A (5 mM DMHA in water adjusted to pH 7.0 with formic acid) and eluent B (5 mM DMHA in 50:50 water:acetonitrile, not pH adjusted) were combined as follows: constant flow, 0.4 ml/ min; time 0 -4.7 min, gradient from 100% A to 20% A; 4.7 -4.8 min, 20-100% A; and 4.8 -6.1 min, isocratic 100% A. Detection of the eluate components was performed using multiple reaction monitoring, with negative electrospray mode with the following m/z transitions: 329.8 . 195.0 (dAMP) and 345.7 . 79.0 (dGMP). Identification of all compounds was based on retention time and specific ion transitions. Calibration curves made with aqueous standards were processed in parallel, and concentrations were obtained from interpolation of the peak areas using TargetLynx software (Waters).
Statistics
Statistical analysis was performed with SPSS 15.0 software. The tests used are indicated in the Results section or the figure legends. For statistical purposes, undetectable values were considered zero.
